Titre : Interventions chirurgicales de cytoréduction

Interventions chirurgicales de cytoréduction : Questions médicales fréquentes

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer un cancer nécessitant une cytoréduction ?

Un diagnostic est établi par imagerie, biopsie et évaluation clinique.
Cancer Biopsie
#2

Quels examens sont utilisés pour évaluer l'extension tumorale ?

Les examens d'imagerie comme l'IRM, le scanner et l'échographie sont courants.
Imagerie par résonance magnétique Tomodensitométrie
#3

Quels marqueurs tumoraux peuvent indiquer une intervention ?

Des marqueurs comme CA-125 pour l'ovaire ou PSA pour la prostate peuvent être utilisés.
Marqueurs tumoraux Antigène spécifique de la prostate
#4

Quelle est l'importance de l'évaluation préopératoire ?

Elle permet de déterminer la faisabilité de la cytoréduction et d'évaluer les risques.
Évaluation préopératoire Risques chirurgicaux
#5

Comment évaluer la réponse au traitement avant la chirurgie ?

On utilise des examens d'imagerie et des tests de laboratoire pour évaluer la réponse.
Réponse au traitement Tests de laboratoire

Symptômes 5

#1

Quels symptômes peuvent indiquer un besoin de cytoréduction ?

Des douleurs abdominales, des masses palpables ou des symptômes obstructifs peuvent survenir.
Douleur abdominale Symptômes obstructifs
#2

Comment les symptômes varient-ils selon le type de cancer ?

Les symptômes dépendent de la localisation et de l'extension de la tumeur.
Localisation tumorale Extension tumorale
#3

Quels signes d'urgence peuvent nécessiter une intervention rapide ?

Des saignements, une obstruction intestinale ou une détresse respiratoire sont critiques.
Saignement Obstruction intestinale
#4

Les symptômes peuvent-ils s'aggraver avant la chirurgie ?

Oui, l'aggravation des symptômes peut survenir en raison de la progression tumorale.
Progression tumorale Symptômes
#5

Comment les symptômes affectent-ils la qualité de vie ?

Les symptômes peuvent réduire la qualité de vie en limitant les activités quotidiennes.
Qualité de vie Activités quotidiennes

Traitements 5

#1

Quels traitements sont associés à la cytoréduction ?

La chimiothérapie et la radiothérapie sont souvent utilisées en complément.
Chimiothérapie Radiothérapie
#2

Quelle est la durée de l'hospitalisation après une cytoréduction ?

L'hospitalisation varie de quelques jours à plusieurs semaines selon la complexité.
Hospitalisation Complexité chirurgicale
#3

Quels sont les objectifs de la cytoréduction ?

Réduire la masse tumorale, améliorer la survie et faciliter les traitements ultérieurs.
Masse tumorale Survie
#4

Comment se déroule une intervention de cytoréduction ?

Elle implique l'ablation chirurgicale de la tumeur et des tissus environnants.
Ablation chirurgicale Tissus environnants
#5

Quelles sont les techniques chirurgicales utilisées ?

Les techniques incluent la laparoscopie et la chirurgie ouverte selon le cas.
Chirurgie laparoscopique Chirurgie ouverte

Complications 5

#1

Quelles sont les complications possibles après une cytoréduction ?

Les complications incluent infections, hémorragies et problèmes de cicatrisation.
Infections Hémorragies
#2

Comment prévenir les infections post-opératoires ?

L'utilisation d'antibiotiques prophylactiques et des soins appropriés de la plaie sont essentiels.
Antibiotiques prophylactiques Soins de plaie
#3

Quels signes indiquent une complication post-chirurgicale ?

Des douleurs intenses, de la fièvre ou des rougeurs autour de la plaie peuvent indiquer une complication.
Douleurs post-opératoires Fièvre
#4

Les complications peuvent-elles affecter le traitement ultérieur ?

Oui, des complications peuvent retarder ou modifier les traitements adjuvants prévus.
Traitements adjuvants Retard de traitement
#5

Comment gérer les complications après la chirurgie ?

La gestion implique un suivi médical régulier et des interventions si nécessaire.
Suivi médical Interventions

Facteurs de risque 5

#1

Quels sont les facteurs de risque pour le cancer nécessitant cytoréduction ?

Les antécédents familiaux, l'âge avancé et certains modes de vie augmentent le risque.
Antécédents familiaux Âge avancé
#2

Comment le tabagisme influence-t-il le risque de cancer ?

Le tabagisme est un facteur de risque majeur pour plusieurs types de cancers.
Tabagisme Cancers
#3

Les facteurs environnementaux jouent-ils un rôle ?

Oui, l'exposition à des substances chimiques et à des radiations peut augmenter le risque.
Exposition environnementale Radiations
#4

Quel rôle joue l'alimentation dans le risque de cancer ?

Une alimentation riche en graisses et pauvre en fruits et légumes peut augmenter le risque.
Alimentation Risque de cancer
#5

Les infections peuvent-elles être des facteurs de risque ?

Certaines infections virales, comme le HPV, sont liées à un risque accru de cancer.
Infections virales Risque accru
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interventions chirurgicales de cytoréduction : Questions médicales les plus fréquentes", "headline": "Interventions chirurgicales de cytoréduction : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interventions chirurgicales de cytoréduction : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-17", "dateModified": "2026-02-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interventions chirurgicales de cytoréduction" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Procédures de chirurgie opératoire", "url": "https://questionsmedicales.fr/mesh/D013514", "about": { "@type": "MedicalCondition", "name": "Procédures de chirurgie opératoire", "code": { "@type": "MedicalCode", "code": "D013514", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "E04" } } }, "about": { "@type": "MedicalCondition", "name": "Interventions chirurgicales de cytoréduction", "alternateName": "Cytoreduction Surgical Procedures", "code": { "@type": "MedicalCode", "code": "D065426", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Álvaro Arjona-Sánchez", "url": "https://questionsmedicales.fr/author/%C3%81lvaro%20Arjona-S%C3%A1nchez", "affiliation": { "@type": "Organization", "name": "General & Digestive Surgery Department, University Hospital Reina Sofía, School of Medicine, University of Córdoba, Córdoba, Spain." } }, { "@type": "Person", "name": "Sang-Yoon Park", "url": "https://questionsmedicales.fr/author/Sang-Yoon%20Park", "affiliation": { "@type": "Organization", "name": "From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.)." } }, { "@type": "Person", "name": "Helene Hurth", "url": "https://questionsmedicales.fr/author/Helene%20Hurth", "affiliation": { "@type": "Organization", "name": "Universitätsklinik für Neurochirurgie, Department für Neurochirurgie und Neurotechnologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland. helene.hurth@med.uni-tuebingen.de." } }, { "@type": "Person", "name": "Johannes Heinzel", "url": "https://questionsmedicales.fr/author/Johannes%20Heinzel", "affiliation": { "@type": "Organization", "name": "Klinik für Hand‑, Plastische, Rekonstruktive und Verbrennungschirurgie, BG Unfallklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Deutschland." } }, { "@type": "Person", "name": "Adrien Daigeler", "url": "https://questionsmedicales.fr/author/Adrien%20Daigeler", "affiliation": { "@type": "Organization", "name": "Klinik für Hand‑, Plastische, Rekonstruktive und Verbrennungschirurgie, BG Unfallklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Deutschland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].", "datePublished": "2023-09-12", "url": "https://questionsmedicales.fr/article/37768120", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } }, { "@type": "ScholarlyArticle", "name": "[Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].", "datePublished": "2023-08-14", "url": "https://questionsmedicales.fr/article/37578542", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00104-023-01937-3" } }, { "@type": "ScholarlyArticle", "name": "Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications.", "datePublished": "2023-11-11", "url": "https://questionsmedicales.fr/article/37951927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13048-023-01303-1" } }, { "@type": "ScholarlyArticle", "name": "The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.", "datePublished": "2023-11-06", "url": "https://questionsmedicales.fr/article/37890875", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/ijgc-2022-004093" } }, { "@type": "ScholarlyArticle", "name": "Cytoreductive nephrectomy in metastatic renal cell carcinoma.", "datePublished": "2024-06-07", "url": "https://questionsmedicales.fr/article/38847285", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD013773.pub2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Procédures de chirurgie opératoire", "item": "https://questionsmedicales.fr/mesh/D013514" }, { "@type": "ListItem", "position": 3, "name": "Interventions chirurgicales de cytoréduction", "item": "https://questionsmedicales.fr/mesh/D065426" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interventions chirurgicales de cytoréduction - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interventions chirurgicales de cytoréduction", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2026-04-28", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interventions chirurgicales de cytoréduction", "description": "Comment diagnostiquer un cancer nécessitant une cytoréduction ?\nQuels examens sont utilisés pour évaluer l'extension tumorale ?\nQuels marqueurs tumoraux peuvent indiquer une intervention ?\nQuelle est l'importance de l'évaluation préopératoire ?\nComment évaluer la réponse au traitement avant la chirurgie ?", "url": "https://questionsmedicales.fr/mesh/D065426#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interventions chirurgicales de cytoréduction", "description": "Quels symptômes peuvent indiquer un besoin de cytoréduction ?\nComment les symptômes varient-ils selon le type de cancer ?\nQuels signes d'urgence peuvent nécessiter une intervention rapide ?\nLes symptômes peuvent-ils s'aggraver avant la chirurgie ?\nComment les symptômes affectent-ils la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D065426#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interventions chirurgicales de cytoréduction", "description": "Quels traitements sont associés à la cytoréduction ?\nQuelle est la durée de l'hospitalisation après une cytoréduction ?\nQuels sont les objectifs de la cytoréduction ?\nComment se déroule une intervention de cytoréduction ?\nQuelles sont les techniques chirurgicales utilisées ?", "url": "https://questionsmedicales.fr/mesh/D065426#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interventions chirurgicales de cytoréduction", "description": "Quelles sont les complications possibles après une cytoréduction ?\nComment prévenir les infections post-opératoires ?\nQuels signes indiquent une complication post-chirurgicale ?\nLes complications peuvent-elles affecter le traitement ultérieur ?\nComment gérer les complications après la chirurgie ?", "url": "https://questionsmedicales.fr/mesh/D065426#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interventions chirurgicales de cytoréduction", "description": "Quels sont les facteurs de risque pour le cancer nécessitant cytoréduction ?\nComment le tabagisme influence-t-il le risque de cancer ?\nLes facteurs environnementaux jouent-ils un rôle ?\nQuel rôle joue l'alimentation dans le risque de cancer ?\nLes infections peuvent-elles être des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D065426#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un cancer nécessitant une cytoréduction ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic est établi par imagerie, biopsie et évaluation clinique." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'extension tumorale ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les examens d'imagerie comme l'IRM, le scanner et l'échographie sont courants." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux peuvent indiquer une intervention ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme CA-125 pour l'ovaire ou PSA pour la prostate peuvent être utilisés." } }, { "@type": "Question", "name": "Quelle est l'importance de l'évaluation préopératoire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de déterminer la faisabilité de la cytoréduction et d'évaluer les risques." } }, { "@type": "Question", "name": "Comment évaluer la réponse au traitement avant la chirurgie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des examens d'imagerie et des tests de laboratoire pour évaluer la réponse." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un besoin de cytoréduction ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs abdominales, des masses palpables ou des symptômes obstructifs peuvent survenir." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon le type de cancer ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent de la localisation et de l'extension de la tumeur." } }, { "@type": "Question", "name": "Quels signes d'urgence peuvent nécessiter une intervention rapide ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements, une obstruction intestinale ou une détresse respiratoire sont critiques." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avant la chirurgie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'aggravation des symptômes peut survenir en raison de la progression tumorale." } }, { "@type": "Question", "name": "Comment les symptômes affectent-ils la qualité de vie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent réduire la qualité de vie en limitant les activités quotidiennes." } }, { "@type": "Question", "name": "Quels traitements sont associés à la cytoréduction ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie et la radiothérapie sont souvent utilisées en complément." } }, { "@type": "Question", "name": "Quelle est la durée de l'hospitalisation après une cytoréduction ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'hospitalisation varie de quelques jours à plusieurs semaines selon la complexité." } }, { "@type": "Question", "name": "Quels sont les objectifs de la cytoréduction ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Réduire la masse tumorale, améliorer la survie et faciliter les traitements ultérieurs." } }, { "@type": "Question", "name": "Comment se déroule une intervention de cytoréduction ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elle implique l'ablation chirurgicale de la tumeur et des tissus environnants." } }, { "@type": "Question", "name": "Quelles sont les techniques chirurgicales utilisées ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la laparoscopie et la chirurgie ouverte selon le cas." } }, { "@type": "Question", "name": "Quelles sont les complications possibles après une cytoréduction ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent infections, hémorragies et problèmes de cicatrisation." } }, { "@type": "Question", "name": "Comment prévenir les infections post-opératoires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation d'antibiotiques prophylactiques et des soins appropriés de la plaie sont essentiels." } }, { "@type": "Question", "name": "Quels signes indiquent une complication post-chirurgicale ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs intenses, de la fièvre ou des rougeurs autour de la plaie peuvent indiquer une complication." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter le traitement ultérieur ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications peuvent retarder ou modifier les traitements adjuvants prévus." } }, { "@type": "Question", "name": "Comment gérer les complications après la chirurgie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des interventions si nécessaire." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le cancer nécessitant cytoréduction ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, l'âge avancé et certains modes de vie augmentent le risque." } }, { "@type": "Question", "name": "Comment le tabagisme influence-t-il le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme est un facteur de risque majeur pour plusieurs types de cancers." } }, { "@type": "Question", "name": "Les facteurs environnementaux jouent-ils un rôle ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances chimiques et à des radiations peut augmenter le risque." } }, { "@type": "Question", "name": "Quel rôle joue l'alimentation dans le risque de cancer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en graisses et pauvre en fruits et légumes peut augmenter le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles être des facteurs de risque ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le HPV, sont liées à un risque accru de cancer." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 06/02/2026

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Álvaro Arjona-Sánchez

2 publications dans cette catégorie

Affiliations :
  • General & Digestive Surgery Department, University Hospital Reina Sofía, School of Medicine, University of Córdoba, Córdoba, Spain.

Sang-Yoon Park

2 publications dans cette catégorie

Affiliations :
  • From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).

Helene Hurth

2 publications dans cette catégorie

Affiliations :
  • Universitätsklinik für Neurochirurgie, Department für Neurochirurgie und Neurotechnologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland. helene.hurth@med.uni-tuebingen.de.
Publications dans "Interventions chirurgicales de cytoréduction" :

Johannes Heinzel

2 publications dans cette catégorie

Affiliations :
  • Klinik für Hand‑, Plastische, Rekonstruktive und Verbrennungschirurgie, BG Unfallklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Publications dans "Interventions chirurgicales de cytoréduction" :

Adrien Daigeler

2 publications dans cette catégorie

Affiliations :
  • Klinik für Hand‑, Plastische, Rekonstruktive und Verbrennungschirurgie, BG Unfallklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Publications dans "Interventions chirurgicales de cytoréduction" :

Jonas Kolbenschlag

2 publications dans cette catégorie

Affiliations :
  • Klinik für Hand‑, Plastische, Rekonstruktive und Verbrennungschirurgie, BG Unfallklinik Tübingen, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Publications dans "Interventions chirurgicales de cytoréduction" :

Martin Schuhmann

2 publications dans cette catégorie

Affiliations :
  • Universitätsklinik für Neurochirurgie, Department für Neurochirurgie und Neurotechnologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
Publications dans "Interventions chirurgicales de cytoréduction" :

Vidhya Gunaseelan

2 publications dans cette catégorie

Affiliations :
  • Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Michigan Opioid Prescribing Engagement Network, Ann Arbor, Michigan.
Publications dans "Interventions chirurgicales de cytoréduction" :

Jennifer F Waljee

2 publications dans cette catégorie

Affiliations :
  • Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Michigan Opioid Prescribing Engagement Network, Ann Arbor, Michigan.
Publications dans "Interventions chirurgicales de cytoréduction" :

Juan José Segura-Sampedro

1 publication dans cette catégorie

Affiliations :
  • Department of General and Digestive Surgery, Son Espases University Hospital, Spain, 07010 Palma de Mallorca, Spain. Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain. School of Medicine, University of the Balearic Islands (UIB), Palma de Mallorca, Spain. segusamjj@gmail.com.
Publications dans "Interventions chirurgicales de cytoréduction" :

Rafael Morales-Soriano

1 publication dans cette catégorie

Affiliations :
  • Department of General and Digestive Surgery, Son Espases University Hospital, Spain, 07010 Palma de Mallorca, Spain. Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
Publications dans "Interventions chirurgicales de cytoréduction" :

Pedro Cascales-Campos

1 publication dans cette catégorie

Affiliations :
  • General & Digestive Surgery Department, University Hospital Virgen de la Arrixaca, School of Medicine, University of Murcia, Murcia, Spain.
Publications dans "Interventions chirurgicales de cytoréduction" :

Stoyan Kostov

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Yavor Kornovski

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Rafał Watrowski

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Stanislav Slavchev

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Yonka Ivanova

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Angel Yordanov

1 publication dans cette catégorie

Publications dans "Interventions chirurgicales de cytoréduction" :

Robert L Coleman

1 publication dans cette catégorie

Affiliations :
  • From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).
Publications dans "Interventions chirurgicales de cytoréduction" :

Nick M Spirtos

1 publication dans cette catégorie

Affiliations :
  • From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).
Publications dans "Interventions chirurgicales de cytoréduction" :

Sources (10000 au total)

[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy].

Peritoneal carcinosis has historically been considered as inoperable, although the technique of its resesection together with high dose intraperitoneal chemotherapy potentiated by heat has been descri...

[Surgical treatment of pseudomyxoma peritonei-Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].

Pseudomyxoma peritonei syndrome (PMP) is an orphan disease. Surgery is the fundament of treatment.... Short review summarizing the state of the art treatment.... Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) form the foundations of treatment for PMP. The peritoneal cancer index should be preoperatively determ... Standardized surgical treatment and HIPEC, optimized specific surgical training and structured follow-up at the center lead to an excellent long-term prognosis for patients with PMP....

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications.

No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing ... R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were u... Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out...

The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.

The peritoneal cancer index quantitatively assesses cancer distribution and tumor burden in the peritoneal cavity. The aim of this study is to evaluate the association between the peritoneal cancer in... This is a single-center prospective cohort observational study. A total of 100 consecutive patients who underwent ovarian cancer surgery were included. Peritoneal cancer index scores prior to and afte... The overall median peritoneal cancer index score was 9.5 (range 0-36). The median age of the patients was 61 years (range 24-85). The most common stage was III (13% stage II, 53% stage III, 34% stage ... In our study we found that a peritoneal cancer index score of ≤20 was associated with a high likelihood of complete cytoreduction. Incorporating the peritoneal cancer index into routine surgical pract...

Cytoreductive nephrectomy in metastatic renal cell carcinoma.

Nephrectomy is the surgical removal of all or part of a kidney. When the aim of nephrectomy is to reduce tumor burden in people with established metastatic disease, the procedure is called cytoreducti... To assess the effects of cytoreductive nephrectomy combined with systemic anticancer therapy versus systemic anticancer therapy alone or watchful waiting in newly diagnosed metastatic renal cell carci... We performed a comprehensive search in the Cochrane Library, MEDLINE, Embase, Scopus, two trial registries, and other gray literature sources up to 1 March 2024. We applied no restrictions on publicat... We included randomized controlled trials (RCTs) that evaluated SACT and CN versus SACT alone or watchful waiting.... Two review authors independently selected studies and extracted data. Primary outcomes were time to death from any cause and quality of life. Secondary outcomes were time to disease progression, treat... Our search identified 10 records of four unique RCTs that informed two comparisons. In this abstract, we focus on the results for the two primary outcomes. Cytoreductive nephrectomy plus systemic anti... CN plus SACT in the form of interferon immunotherapy versus SACT in the form of interferon immunotherapy alone probably increases time to death from any cause. However, we are very uncertain about the...

Optimal cytoreduction: is a CT's picture worth a surgeon's word?

The presence of residual disease after cytoreductive surgery is subjectively determined by the surgeon at the end of the operation. Nevertheless, in up to 21-49% of CT scans, residual disease can be f... Patients with advanced ovarian cancer (FIGO II and IV), diagnosed between 2007 and 2019 in Hospital La Fe Valencia, in whom cytoreductive surgery was performed, achieving R0 or R1, were assessed for e... 117 patients were finally included. The CT findings were classified into three categories: no evidence, suspicious or conclusive of residual tumour/progressive disease. 29.9% of CT scans were "conclus... After cytoreduction in ovarian cancer with no macroscopic disease or residual tumour < 1 cm result, up to 29.9% of post-operative CT scans before chemotherapy found measurable residual or progressive ...

Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery.

The delivery of multimodal treatment at a high-volume center is known to optimize the outcomes of gastrointestinal malignancies. However, patients undergoing cytoreductive surgery (CRS) for peritoneal... Adults undergoing CRS for colorectal or appendiceal adenocarcinoma at our institution between 2016 and 2022 were identified retrospectively and grouped by care network: 'coordinated care' patients rec... Among 85 (80%) patients, 47 (55%) had colorectal primaries and 51 (60%) received fragmented care. Greater travel distance [OR 1.01 (CI 1.00-1.02), p = 0.02] and educational status [OR 1.04 (CI 1.01-1.... There were no significant differences in survival or SAEs based on the networks of systemic therapy delivery. This suggests that patients undergoing CRS at a high-volume center may safely receive syst...

[Experience of cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy in ovarian cancer].

Currently, epithelial ovarian cancer is diagnosed in advanced stages (EC IIIC) in 75-80% of cases worldwide. In this group of patients treatment with neoadjuvant chemotherapy is started, followed by i... To identify the overall survival and progression-free survival associated with peritonectomy, in patients with peritoneal carcinomatosis secondary to ovarian cancer treated in the oncology gynecology ... Observational, descriptive, cross-sectional, retrospective study, information was obtained from the clinical file of patients treated with peritonectomy with the use of hyperthermic intraperitoneal ch... Information was obtained from a total of 36 patients (n=100%), 36.1% received intraperitoneal chemotherapy and 63.8% underwent cytoreduction without the application of intraoperative chemotherapy. The... Peritonectomy with hyperthermic intraperitoneal chemotherapy is an option in selected patients with advanced stage ovarian cancer in primary and recurrent surgery, as well as in patients with platinum...

Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis.

Peritoneal metastasis (PM) is the most common site of dissemination of gastric cancer (GC) and is associated with a poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoth... We conducted a retrospective analysis of patients with GC and PM treated with CRS and HIPEC with cisplatin and paclitaxel for 90 min from June 2019 to December 2022.... Twenty-two patients were included and received a median of 7 (interquartile range [IQR] 4-8) cycles of neoadjuvant systemic therapy. Seventeen patients (77%) underwent a single neoadjuvant laparoscopi... CRS and HIPEC with paclitaxel and cisplatin is well tolerated and is associated with favorable oncologic and perioperative outcomes....

Postoperative complications in women with ovarian cancer stratified by cytoreductive surgery outcome.

To compare 30-day postoperative complications for patients with advanced ovarian cancer who underwent resection to no gross residual disease versus optimal and suboptimal cytoreduction.... A retrospective cohort study of women drawn from the National Surgical Quality Improvement Program who underwent cytoreductive surgery for advanced ovarian cancer between 2014 and 2019 was performed. ... A total of 2248 women underwent cytoreductive surgery; 68.4% (n = 1538) underwent resection to no gross residual disease, 22.4% (n = 504) had an optimal, and 9.2% (n = 206) had a suboptimal cytoreduct... Patients who underwent optimal cytoreduction had more postoperative complications, required the most operating room time, and represented more complex surgeries compared with suboptimal cytoreduction ...